Mitos Therapeutics Inc. is a biotech venture founded in 2020 on the research of the Department of Pharmacology, Chungnam National University College of Medicine, and based in Daejeon, South Korea.

We develop first-in-class therapeutics for sarcopenia — age-related loss of muscle mass and strength — using targeted protein degradation (TPD) technology, together with functional food ingredients for muscle health. Our lead candidate, MTPD-101, is in preclinical development under the Korea Drug Development Fund (KDDF) program.

Our focus is to fine-tune our energy metabolism to restore aging health. Health can be regarded as the result of our bodies' successful adaptation to the environment, maintaining a homeostatic balance, and appropriately recognizing and responding to energy imbalance.

Cellular energy metabolism plays an important role in health by controlling energy intake and energy consumption. Therefore, it has evolved to respond to the changes in the proper ways to support our health and well-being.

However, our energy metabolism can sometimes react improperly, resulting in chronic or severe disease. Our goal is to find treatments that can control the energy balance to restore cell energy metabolism capabilities in a disease state.

"Mitos" is a word for strings that are part of mitochondria, chosen because mitochondrial-based cell energy metabolism is our subject of study.

Meet our team